Macrophages: The neglected barrier to eradication

Current Opinion in Infectious Diseases

Volumn 26, Issue 6, 2013, Pages 561-566

  Watters, Sarah A ^a   Mlcochova, Petra ^a   Gupta, Ravindra K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antiretroviral therapy; eradication; HIV 1; macrophages; reservoir

Indexed keywords

ABACAVIR; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BELINOSTAT; EFAVIRENZ; ETRAVIRINE; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTEGRASE INHIBITOR; LAMIVUDINE; MARAVIROC; NEVIRAPINE; PANOBINOSTAT; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

CD8+ T LYMPHOCYTE; CELL LINE; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MONOCYTE; NONHUMAN; REVIEW; VIRAL CLEARANCE; VIRUS REACTIVATION; VIRUS REPLICATION;

ANIMALS; ANTI-RETROVIRAL AGENTS; DISEASE RESERVOIRS; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; MONOCYTES; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 84887321093     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000014     Document Type: Review

References (89)

1. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5delta32/ delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.
2. Henrich TJ, Hanhauser E, Sirignano M. et al. In depth investigation of peripheral and gut HIV-1 reservoirs, HIV-specific cellular immunity, and host microchimerism following allogeneic hematopoietic stem cell transplantation [abstract]. In: Abstract Book, Towards an HIV Cure Symposium 29-30 June, Kuala Lumpur, Malaysia. International AIDS Society; 2013. Abstr. OA1-1.
3. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV-1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013; 207:1694-1702.
4. Persaud D, Gay H, Ziemniak CF. Functional HIV cure after very early ART of an infected infant [abstract]. In: 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March, 2013, Atlanta, GA; 2013. Abstr. 48LB.
5. Thieblemont N, Weiss L, Sadeghi HM, et al. CD14lowCD16high: a cytokineproducing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol 2005; 25:3418-3424.
6. Wang T, Xu Y, Zhu H, et al. Successful isolation of infectious and high titer human monocyte-derived HIV-1 from two subjects with discontinued therapy. PLoS One 2013; 8:e65071.
7. Fischer-Smith T, Croul S, Sverstiuk AE, et al. CNS invasion by CD14/ CD16 peripheral blood-derived monocytes in, HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol 2001; 7:528-541.
8. Ellery PJ, Tippett E, Chiu Y-L, et al. The CD16 monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 2007; 178:6581-6589.
9. Xu Y, Zhu H, Wilcox CK, et al. Blood monocytes harbor HIV type 1 strains with diversified phenotypes including macrophage specific CCR5 virus. J Infect Dis 2008; 197:309-318.
10. Weber C, Belge KU, Hundelshausen von P, et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol 2000; 67:699-704.
11. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997; 276:1857-1861.
12. Koppensteiner H, Banning C, Schneider C, et al. Macrophage internal HIV-1 is protected from neutralizing antibodies. J Virol 2011; 86:2826-2836.
13. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191.
14. Igarashi T, Brown CR, Endo Y, et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4 T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for the HIV-1 infections of humans. Proc Natl Acad Sci U S A 2001; 98:658-663.
15. Blankson JN, Finzi D, Pierson TC, et al. Biphasic decay of latently infected CD4 T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:1636-1642.
16. Swingler S, Mann AM, Zhou J, et al. Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog 2007; 3:e134.
17. Busca A, Saxena M, Kumar A. Critical role for antiapoptotic Bcl-xL and Mcl-1 in human macrophage survival and cellular IAP1/2 (cIAP1/2) in resistance to HIV-Vpr-induced apoptosis. J Biol Chem 2012; 287:15118-15133.
18. Mlc? ochová P, Pelchen-Matthews A, Marsh M. Organization and regulation of intracellular plasma membrane-connected HIV-1 assembly compartments in macrophages. BMC Biol 2013; 11:89.
19. Caselli E, Galvan M, Cassai E, et al. Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. Blood 2005; 106:2790-2797.
20. Lambotte O, Taoufik Y, De Goer MG, et al. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 23:114-119.
21. Sonza S, Mutimer HP, Oelrichs R, et al. Monocytes harbour replicationcompetent, nonlatent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001; 15:17-22.
22. Ortiz AM, Klatt NR, Li B, et al. Depletion of CD4 T cells abrogates postpeak decline of viremia in SIV-infected rhesus macaques. J Clin Invest 2011; 121:4433-4445.
23. Vojnov L, Martins MA, Bean AT, et al. The majority of freshly sorted simian immunodeficiency virus (SIV)-specific CD8 T cells cannot suppress viral replication in SIV-infected macrophages. J Virol 2012; 86:4682-4687.
24. Coiras M, Lopez-Huertas MIAR, Perez-Olmeda M, Alcam J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nature Rev. Microbio 2009; 7:798-812.
25. Chun T-W, Nickle DC, Justement JS, et al. Persistence of HIV in gutassociated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 97:714-720.
26. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202:1553-1561.
27. Gonzá lez-Scarano F, Mart?́n-Garc?́a J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5:69-81.
28. Davis LE, Hjelle BL, Miller VE, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992; 42:1736-1739.
29. Williams DW, Calderon TM, Lopez L, et al. Mechanisms of HIV entry into the CNS: increased sensitivity of HIV infected CD14CD16 monocytes to CCL2 and key roles of CCR2, JAM-A, and ALCAM in diapedesis. PLoS One 2013; 8:e69270.
30. Williams KC. Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 2001; 193:905-916.
31. Fischer-Smith T, Bell C, Croul S, et al. Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J Neurovirol 2008; 14:318-326.
32. Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012; 206:275-282.
33. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995; 38:755-762.
34. Schnell G, Spudich S, Harrington P, et al. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog 2009; 5:e1000395.
35. Lamers SL, Gray RR, Salemi M, et al. HIV-1 phylogenetic analysis shows HIV-1 transits through the meninges to brain and peripheral tissues. Infect Genet Evol 2011; 11:31-37.
36. Li S, Juarez J, Alali M, et al. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J Virol 1999; 73:9741.
37. Dunfee RL, Thomas ER, Wang J, et al. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology 2007; 367:222-234.
38. Dunfee RL, Thomas ER, Gorry PR, et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A 2006; 103:15160-15165.
39. Zink C, Brice AK, Kelly KM, et al. SIV-infected macaques treated with highly active antiretroviral therapy (HAART) have reduced CNS virus replication and inflammation but persistence of viral DNA. J Infect Dis 2010; 202:161.
40. Graham DR, Gama L, Queen SE, et al. Initiation of HAART during acute simian immunodeficiency virus infection rapidly controls virus replication in the CNS by enhancing immune activity and preserving protective immune responses. J Neurovirol 2011; 17:120-130.
41. Dallas S, Schlichter L, Bendayan R.Multidrug resistance protein (MRP) 4-and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia. J Pharmacol Exp Ther 2004; 309:1221-1229.
42. Jorajuria S, Dereuddre-Bosquet N, Becher F, et al. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther 2004; 9:519-528.
43. Gillim-Ross L, Cara A, Klotman ME. HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages. Viral Immunol 2005; 18:190-196.
44. Gray LR, Tachedjian G, Ellett AM, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One 2013; 8:e62196.
45. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
46. Churchill M, Nath A. Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS 2013; 8:165-169.
47. Gavegnano C, Schinazi RF. Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother 2009; 20:63-78.
48. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732.
49. Surdo M, Balestra E, Saccomandi P, et al. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages. PLoS One 2013; 8:e68076.
50. Rossi R, Lichtner M, De Rosa A, et al. In vitro effect of antihuman immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol 2011; 166:184-190.
51. Roche M, Jakobsen MR, Sterjovski J, et al. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol 2011; 85:4330-4342.
52. Flynn JK, Paukovics G, Moore MS, et al. The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology 2013; 442:51-58.
53. Scopelliti F, Pollicita M, Ceccherini-Silberstein F, et al. Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. Antiviral Res 2011; 92:255-261.
54. Marsden MD, Avancena P, Kitchen CMR, et al. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob Agents Chemother 2011; 55:3696-3702.
55. Michelini Z, Galluzzo CM, Negri DRM, et al. Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based singlecycle phenotypic assay. J Virol Methods 2010; 168:272-276.
56. Yilmaz A, Gisslén M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009; 4:e6877.
57. Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis 2011; 204:1936-1945.
58. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37:377-388.
59. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013; 9:e1003347.
60. Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV patients on and off HAART. PLoS Pathog 2011; 7:e1001300.
61. Matalon S, Palmer BE, Nold MF, et al. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4 T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 2010; 54:1-9.
62. Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013; 9:13-21.
63. Banerjee C, Archin N, Michaels D, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 2012; 92:1147-1154.
64. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5 delta 32/delta 32 stem cell transplantation. Blood 2011; 117:2791-2799.
65. Hatziioannou T, Evans DT. Animal models for HIV/AIDS research. Nature Rev. Microbio 2012; 10:852-867.
66. Dinoso JB, Rabi SA, Blankson JN, et al. A simian immunodeficiency virusinfected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83:9247-9257.
67. Shytaj IL, Norelli S, Chirullo B, et al. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 2012; 8:e1002774.
68. Malzahn J, Shen C, Caurson L, et al. Effect of early antiretroviral therapy on the pathogenic changes in mucosal tissues of SIV infected rhesus macaques. Virology 2012; 9:269.
69. Fukasawa M, Miura T, Hasegawa A, et al. Sequence of simian immunodeficiency virus from African green monkey, a new member of the HIV/SIV group. Nature 1988; 333:457-461.
70. Belshan M, Kimata JT, Brown C, et al. Vpx is critical for SIVmne infection of pigtail macaques. Retrovirology 2012; 9:32.
71. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474:654-657.
72. Hatziioannou T, Ambrose Z, Chung NPY, et al. A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A 2009; 106:4425-4429.
73. Thippeshappa R, Polacino P, Yu Kimata MT, et al. Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol 2011; 85:3767-3779.
74. Aggarwal A, McAllery S, Turville SG. Revising the role of myeloid cells in HIV pathogenesis. Curr HIV/AIDS Rep 2013; 10:3-11.
75. Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 2013; 435:14-28.
76. Rehwinkel J, Maelfait J, Bridgeman A, et al. SAMHD1-dependent retroviral control and escape in mice. EMBO J 2013; 32:2454-2462.
77. Nixon CC, Vatakis DN, Reichelderfer SN, et al. HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 2013; 122:2195-2204.
78. Krotova O, Starodubova E, Petkov S, et al. Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4 and CD8 T cells. PLoS One 2013; 8:e62720.
79. Krisko JF, Martinez-Torres F, Foster JL, Garcia JV. HIV restriction by APOBEC3 in humanized mice. PLoS Pathog 2013; 9:e1003242.
80. Ringpis G-EE, Shimizu S, Arokium H, et al. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One 2012; 7:e53492.
81. Chateau ML, Denton PW, Swanson MD, et al. Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS One 2013; 8:e60024.
82. Kambe N, Hiramatsu H, Shimonaka M, et al. Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body. Blood 2004; 103:860-867.
83. Sun Z, Denton PW, Estes J, et al. Intrarectal transmission, systemic infection, and CD4 T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007; 204:705-714.
84. Denton PW, Estes JD, Sun Z, et al. Antiretroviral preexposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5:e16.
85. Denton PW, Othieno F,Martinez-Torres F, et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 2011; 85:7582-7593.
86. Denton PW, Krisko JF, Powell DA, et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 2010; 5:e8829.
87. Denton PW. Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol 2012; 20:268-274.
88. Caligioni CS. Assessing reproductive status/stages in mice. Curr Prot Neurosci 2009; APPENDIX: Appendix-41. doi:10. 1002/0471142301.
89. Evans DT, Silvestri G. Nonhuman primate models in AIDS research. CurrOpin HIV AIDS 2013; 8:255-261.